tetano
Editor, Senior Moderator
Infection
. 2021 Jan 2;1-10.
doi: 10.1007/s15010-020-01557-7. Online ahead of print.
Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
Hui Xian Jaime Lin[SUP] 1 [/SUP], Sanda Cho[SUP] 2 [/SUP], Veeraraghavan Meyyur Aravamudan[SUP] 3 [/SUP], Hnin Yu Sanda[SUP] 4 [/SUP], Raj Palraj[SUP] 5 [/SUP], James S Molton[SUP] 6 [/SUP], Indumathi Venkatachalam[SUP] 7 [/SUP]
Affiliations
Abstract
COVID-19 is an infectious disease caused by a novel β-coronavirus, belonging to the same subgenus as the Severe Acute Respiratory Syndrome (SARS) virus. Remdesivir, an investigational broad-spectrum antiviral agent has previously demonstrated in vitro activity against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and in vivo efficacy against other related coronaviruses in animal models. Its safety profile has been tested in a compassionate use setting for patients with COVID-19. The current therapeutic studies demonstrate clinical effectiveness of remdesivir in COVID-19 patients by shortening time to clinical recovery, and hospital stay. In this review, we critically analyze the current evidence of remdesivir against COVID-19 and dissect the aspects over its safety and efficacy. Based on existing data, remdesivir can be regarded as a potential therapeutic agent against COVID-19. Further large-scale, randomized placebo-controlled clinical trials are, however, awaited to validate these findings.
Keywords: COVID-19; Hui Xian Jaime Lin and Sanda Cho shared the first authorship; Remdesivir; SAR-CoV-2.
. 2021 Jan 2;1-10.
doi: 10.1007/s15010-020-01557-7. Online ahead of print.
Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
Hui Xian Jaime Lin[SUP] 1 [/SUP], Sanda Cho[SUP] 2 [/SUP], Veeraraghavan Meyyur Aravamudan[SUP] 3 [/SUP], Hnin Yu Sanda[SUP] 4 [/SUP], Raj Palraj[SUP] 5 [/SUP], James S Molton[SUP] 6 [/SUP], Indumathi Venkatachalam[SUP] 7 [/SUP]
Affiliations
- PMID: 33389708
- PMCID: PMC7778417
- DOI: 10.1007/s15010-020-01557-7
Abstract
COVID-19 is an infectious disease caused by a novel β-coronavirus, belonging to the same subgenus as the Severe Acute Respiratory Syndrome (SARS) virus. Remdesivir, an investigational broad-spectrum antiviral agent has previously demonstrated in vitro activity against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and in vivo efficacy against other related coronaviruses in animal models. Its safety profile has been tested in a compassionate use setting for patients with COVID-19. The current therapeutic studies demonstrate clinical effectiveness of remdesivir in COVID-19 patients by shortening time to clinical recovery, and hospital stay. In this review, we critically analyze the current evidence of remdesivir against COVID-19 and dissect the aspects over its safety and efficacy. Based on existing data, remdesivir can be regarded as a potential therapeutic agent against COVID-19. Further large-scale, randomized placebo-controlled clinical trials are, however, awaited to validate these findings.
Keywords: COVID-19; Hui Xian Jaime Lin and Sanda Cho shared the first authorship; Remdesivir; SAR-CoV-2.